Multiplex Immunoassay by EMMB Platform
Contribution for point of care testing (POCT)
Multiplexedpoint of care testing is simultaneous on-site detection different analytes froma single specimen. Recently, it has become more and more important for clinical diagnostics. WinMEMS, a joint venture company with U-GEN, owns the proprietary technology, EdgeCode® Multiplex Magnetic Beads (EMMB). Through the coupling processes, each bead can be tagged with a bio-probe that is used to identify a particular nucleic acid sequence in the case of a molecular assay or a particular protein antigen or antibody in the case of an immunoassay. The unique and patented EMMB is a powerful and efficient coding system allowing to detect up to 4,096 biomarkers for multiplexed testing.
Potential Applications of Multiplex Testing
Through WinMEMS’ state-of-the-art multiplex diagnostic system, more precise, comprehensive, fast and cost-effective IVD testing kits can be developed. Additionally, the platform can also apply to diagnostics for the detection of animal and plant diseases, food safety, as well as for environmental protection. Currently, several studies are ongoing, including detection kits for:
sepsis strains and effective antibiotics
diabetic associated diseases
early tumor screening
dementia
